Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma

NCT01899599 is registered in ClinicalTrials.gov with Glycotope GmbH as lead sponsor.

NCT NCT01899599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01899599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma
Lead sponsor
Glycotope GmbH
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2013
Completion date
July 28, 2017
Enrollment
216 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian epithelial cancer recurrent, primary peritoneal cancer